Dosing schedule that meets your patients' needs
High and sustained Factor IX levels at steady state in clinical trials1,†
Zero median annualized spontaneous bleeding rate (AsBR) when dosed at 7 or 14 days in clinical trials
*In patients 12 years and older on a weekly dose of ≤40 IU/kg for 1 month without spontaneous bleeding. †Steady-state levels measured FIX at trough levels before each infusion every four weeks until week 92 at 7-day prophylaxis and week 104 at 14-day prophylaxis. FIX levels were 13% when dosed every 14 days.
CSL Behring is committed to providing treatments and supportive services that make a meaningful difference in the lives of people with bleeding disorders.
Resources available to help ensure your patients get the treatment they need for hemophilia B include: